Answers are grounded in this paper and cite their sources.
In patients with RA or SpA and secondary failure, the development of ADA against ADL or INF, but not ETN, appears to be one of the main reasons for secondary treatment failure, but not the only one. Further investigations are needed to determine other causes of anti-TNF failure.
No takes yet. Share an insight, caveat, or question.
Balsa et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: